Genitrix is encouraging practices to capitalise on the growing market opportunity for dental treatments by offering a free pack of its Dentagen Dental Wax and a special offer of six products for the price of five for the rest of its Dentagen dental range during March 2010.
The company is also urging practices to declare March 'Dental Care Month' and to use it as a platform to step up the education they offer to pet owners on this important welfare issue.
According to Genitrix, the Dentagen range uses a plant extract called RF2 which operates as an 'anti-biofilm' treatment, modifying the membrane of oral bacteria to prevent them from producing plaque even at low concentrations. Dentagen Wax is applied to dogs or cats at the end of dental procedures in practice, while the animal is still sedated. It forms a protective coating over the teeth, which lasts for several days.
Each pack of wax contains five syringes enabling practices to offer free wax applications to pets during Dental Care Month. Pet owners can then maintain the protective coating by giving their pet either Dentagen plaque prevention chews every other day or the Dentagen Aqua drinking water additive.
For dogs, the chews are supplied in two sizes with the larger size designed for dogs over 8 kg and a smaller size for dogs less than 8 kg. Dentagen Aqua is a drinking water additive containing RF2. The company says the palatable liquid, which is added to a pet's drinking water, has proved particularly effective in treating cats which don't respond well to tooth-brushing or dental chews.
Rob Watkins, Genitrix' marketing director said: "It's well known that dental disease affects 80% of pets over three years' old and, if left untreated, can go on to cause serious health problems.
"Data from veterinary practices also confirms that many of them are not achieving the revenue they could from offering dental treatments to their clients. We want them to get their teeth into this important revenue opportunity so we're calling on practices to make March 'Dental Care Month' and are offering them a special deal on Dentagen products to get them started.
"The efficacy of the Dentagen range in inhibiting plaque formation has been proven in clinical trials and it has proved popular with pet owners, increasing their compliance with preventative health regimes."
To order your free pack of Dentagen Wax and to take advantage of the special offer on the rest of the range, contact Genitrix on 01403 786345 or by email at mail@genitrix.co.uk
A new paper by D J Bartram and D S Baldwin, published in this week's Veterinary Record, has found that veterinary surgeons are four times as likely as the general public, and around twice as likely as other healthcare professionals, to die by suicide as opposed to other causes.
Professor Bill Reilly, President of the British Veterinary Association, said: "David Bartram's research in this difficult area is to be applauded. The more we can understand about the reasons behind the high suicide rate amongst veterinary surgeons, the more the BVA and other bodies can do to support vets in crisis.
"As part of the Vetlife Steering Group, the BVA supports fantastic initiatives such as the 24-hour Vet Helpline for vets, vet nurses and veterinary students, and the Veterinary Benevolent Fund.
"The BVA's Member Services Group (MSG) also spends a lot of time looking at practical initiatives to improve individual vets' day-to day lives. The recent introduction of the mediation and representation services to help resolve issues between veterinary employees and veterinary employers is a good example of the positive ways in which the BVA can support its members in difficult situations.
"The MSG also recently produced a helpline sticker for all veterinary practices to display on the medicines cabinet and other prominent places to act as a constant reminder that help is available.
"Ours is a small profession and many vets will know a friend or colleague who has taken their own life. It is essential that this issue is kept in the open so that those who are struggling know where to turn for help."
Guillaume Fournié and Dr Javier Guitian from the Royal Veterinary College - working with colleagues from the London School of Hygiene and Tropical Medicine and Imperial College - have developed a model to understand how live bird markets act as a "hub" of infection for domestic poultry and if rest days, during which such markets are emptied and disinfected, may reduce transmission.
The results are published today in Interface - the Journal of The Royal Society. PhD student Guillaume Fournié, who led the research, said: "Live bird markets can be a reservoir of infection for domestic poultry and may therefore be responsible for sustaining H5N1 HPAI virus circulation.
"Compared to interventions applied in farms - such as stamping out and vaccination - our model shows that frequent rest days are an effective means with which to reduce H5N1 HPAI infection rates. Furthermore, our model predicts that full market closure - as has been implemented in some countries such as Egypt and Vietnam - would only be slightly more effective than rest days to reduce transmission of the disease."
The models used in the study are based on the live bird market chain in Hong Kong and the analysis restricted to chickens. Fournié, who qualified to be a vet in Alfort in his native France, was awarded fully-funded studentships (tuition fees and a living allowance) in 2007 by The Bloomsbury Colleges - a consortium of six colleges of the University of London: Birkbeck, IoE, LSHTM, RVC, School of Oriental and African Studies, and The School of Pharmacy - to conduct the research.
Since December 2003 outbreaks of H5N1 Highly Pathogenic Avian Influenza (HPA1) affecting domestic poultry have been reported in 50 countries across the world. Massive economic losses and the pandemic threat make H5N1 HPAI one of the greatest current public health concerns.
A full copy of the report can be seen in Interface at http://rsif.royalsocietypublishing.org
Zoetis has released new surveillance results which show that Mycoplasma bovis is becoming an increasingly significant pneumonia pathogen in cattle1.
In more than 2,500 samples submitted by vets for analysis during 2014, 45% were positive, compared with 41% in 2013.
According to Dr Tim Potter MRCVS from Westpoint Veterinary Group, Mycoplasma bovis has emerged as an important pathogen of calves worldwide2. He said: "It is associated with a number of clinical presentations including respiratory disease, otitis media and arthritis.
"The role of Mycoplasma bovis in pneumonia is well established and there are a number of reports in the literature of respiratory disease outbreaks where it was the predominant bacterium isolated. However, as with most causes of pneumonia, colonisation by Mycoplasma bovis alone is not always sufficient to cause disease and it may present in combination with other respiratory pathogens."
For other pathogens, the surveillance found 83% of samples positive for Para-influenza 3 virus (Pi3v), 76% Bovine Respiratory Syncytial virus (BRSv), 32% IBR, and 25% for BVD. Apart from BVD, which saw a three-point reduction from 28% the previous year - these show little change from 2013.
According to Zoetis vet Carolyn Hogan, in pneumonia outbreaks involving Mycoplasma bovis, many of the clinical signs are similar to those caused by other pneumonia pathogens: coughing, raised temperature, rapid breathing and lethargy.
She said: "This can make it difficult for farmers and vets alike to identify Mycoplasma bovis as a possible cause of disease based on clinical signs alone, unless calves are also showing some of the other distinguishing signs associated with Mycoplasma infection.
"These include ear infections, head shaking or tilting, and arthritis. Poor response to treatment, with resulting chronic respiratory cases, may also be suggestive of Mycoplasma infection. For a definitive diagnosis, of course, analysis of blood or respiratory tract mucous is required."
Whilst vaccination protection is available against the viruses (BRSv, Pi3v, BVD and IBR) and Mannheimia (Pasteurella) haemolytica, Carolyn points out that there is no ‘off the shelf’ vaccine available for Mycoplasma bovis. She adds that treatment can be challenging due to the insidious nature of disease, and lack of effectiveness of some antibiotics.
Once Mycoplasma bovis is present on a farm, Carolyn cautions that eradication can be very difficult. "It can be transmitted in milk from carrier cows, and in saliva among calves, particularly when multiple animals suckle the same teat feeders.
"Minimising this pathogen's impact on health and productivity relies on reducing its exposure to susceptible animals and maximising their resilience against it. For a comprehensive programme of control measures, farmers should consult their vet."
Carolyn suggests that such a programme is likely to include: testing the farm's Mycoplasma bovis status; effective biosecurity; not feeding infected milk; ample ventilation for adults and youngstock alike; rapid spotting of sick animals, isolation and vet-prescribed treatment; vigilance for poor response to treatment and development of chronic cases; vaccination against main viral pneumonia pathogens; and low stress through good stockmanship.
References
Photo: By Y tambe (Y tambe's file) [GFDL, CC-BY-SA-3.0 or CC BY-SA 2.5-2.0-1.0], via Wikimedia Commons
Alfaxan®, Vetoquinol's injectable general anaesthetic, is one year old this month. To celebrate the occasion, and the product's use by 860 UK practices in over 80,000 procedures so far, Vetoquinol is offering a free Alfaxan party bag.
The party bag includes an Alfaxan anaesthesia monitoring chart and an Alfaxan vet brochure with dosage chart and timer. In addition, everyone who claims a party bag will be entered into a lucky dip. Ten winners will be chosen at random to receive an oesophageal stethoscope kit, containing one normal stethoscope, with a removable head, and three Portex oesophageal stethoscope probes (small, medium and large) for monitoring patient’s heart and respiratory rate.
To claim your party bag, call the dedicated Alfaxan technical support line on 0800 345 7560 or email: MyAlfaxanPartyBag@vetoquinol.co.uk.
Vetoquinol also reports a very positive response to Alfaxan from the profession during its first year. Simon Boulton, one of Vetoquinol’s Veterinary Advisors, has been conducting wet labs across the country for the company. He said: "Vets have used the wet lab service to get me along to anaesthetize patients for the day using Alfaxan. I have had a great deal of positive feedback and the product is becoming more and more widely used. Extremely smooth and reliable inductions, followed by good cardiovascular and respiratory stability were the most noticeable features of Alfaxan anaesthesia, liked by both the vets anaesthetizing the patients and the nurses who monitor them."
Intervet/Schering-Plough has launched Vectin chewable tablets, an ivermectin wormer for horses which is administered as a treat straight from the hand rather than in the traditional paste or granule formulation.
According to the company, syringe handling, horse acceptance and the tendency to spit out some or all of the paste are common problems reported by owners when worming their horses, and more than 55% admit that these issues can result in a mixture of emotions, including frustration, anxiety and upset.
Field studies with Vectin showed more than 70% spontaneous acceptance by horses and the simple calculation of one tablet for every 110kg of a horse or foal's bodyweight helps to reduce wastage as unused tablets can be stored away for future use.
Pharmacokinetics studies have demonstrated improved bioavailability (AUC) and maximal concentration (Cmax) when compared with an equivalent competitor ivermectin paste formulation. Trials have also shown that a more consistent blood concentration of ivermectin when given as a chew which could potentially limit the chance of inducing resistance.
Intervet/Schering Plough says that used as part of a strategic worming plan, Vectin chewable tablets control potentially a wide range of endoparasites including small and large strongyles, stomach worms, cutaneous worms and stomach bots.
Vectin chewable tablets are available as a seven-tablet blister pack, perfect for treating a horse or a couple of ponies. For yards, a tub of 60 tablets is available, containing enough to dispense product for worming approximately 12 horses.
Vectin chewable tablets are recommended for use alongside Pyratape P and Panacur in Intervet/Schering-Plough Animal Health's Active3 worming plan, a strategic three-year approach to rotating wormers in order to minimize the risk of resistance developing. Visit http://www.intervet.co.uk/ for a copy of the three-year plan.
The European Parliament has voted 618 votes to 17 for an extension to the transitional arrangements contained within the regulation on the non-commercial movement of pet animals which afford the UK additional protection against rabies, ticks and tapeworms.
The British Veterinary Association (BVA) and British Small Animal Veterinary Association (BSAVA) have been lobbying MEPs to support the extension and have strongly welcomed this decision.
The transitional arrangements allow the UK to impose stricter measures on the entry of pet animals and are designed to protect the UK from rabies, ticks and tapeworms (Echinococcus multilocularis).
The vote in the European Parliament today supports an extension of these arrangements until the end of 2011 and puts in place a system so that permanent measures can be imposed in the future for entry to specific Member States based on scientific evidence. The decision will have to be ratified by the European Agriculture Council before coming into force.
Parasitologist Maggie Fisher from ESCCAP said: "This provides the UK with invaluable time to mount a solid scientific case for retaining the requirement for tick and tapeworm treatment indefinitely."
Professor Bill Reilly, President of the BVA, said: "The BVA and BSAVA have worked closely with Defra to secure this extension to the arrangements and we will now be pushing for investment in additional scientific research that will give us a clearer picture of the threat of the parasite Echinococcus multilocularis and other exotic and emerging diseases."
Dr Richard Dixon, President of BSAVA, added: "This decision in Europe is strongly welcomed and we are pleased that veterinary associations across Europe supported our position. The next stage is to gather further evidence to ensure the UK is protected in the future.
"In the meantime, the key message for pet owners is that they must talk to their vets as early as possible to find out how to protect them from disease and parasites when travelling abroad."
Ceva Animal Health has produced a leaflet to help horse owners understand the cause, diagnosis and management of equine back pain.
The company says the management of back pain in the horse can be a particular challenge to vets and a source of frustration for owners. Early diagnosis is likely to be associated with a more favourable outcome but it's important to ensure that other causes of pain and poor performance such as lameness, are not contributing to the horse's clinical signs.
'Understanding back pain' explains the anatomy of the back, as well as the clinical signs of back pain, and how it is diagnosed, including the treatment options and the general prognosis. Copies of the new leaflet are available, free of charge, from your Ceva sales representative. Leaflets on 'Understanding bone spavin', 'Understanding navicular disease', 'Understanding sacroiliac disease' and 'Equidronate discharge instructions', are also available.
For further information contact your local Ceva representative or Ceva Animal Health Ltd, Unit 3, Anglo Office Park, White Lion Road, Amersham, Bucks, HP7 9FB, Telephone +44 (0) 1494 781510.
The collaborative study, which was sponsored by Norbrook, involved each practice blood testing a cohort of six lambs on 25 individual farms from 16 weeks of age, to look for evidence of antibodies to liver fluke.
Only 11 farms had positive results in the period from June, up to December, with most only showing one or two lambs out of the six sero-converting later in the year. Even farms located reasonably close by showed positive cases months apart.
Mark Thompson of Craven Farm Vets in Yorkshire said, “I did not expect to see positive results as late in the year. I expected a positive result earlier (September/October) as the farm is a very wet farm with a long-standing issue with fluke. Also, the weather in the area has been ideal for the intermediate host and fluke development on the pasture.”
Emily Baxter of Drove Farm Vets in Wiltshire said she thinks there is scope to use the results to improve the timing of dosing with flukicides and more responsible use: “We will use the results from this year’s testing to re-evaluate the farm’s fluke control protocol which will help reduce the level of use of flukicides earlier in the season for years with similar weather patterns and assist in planning of strategic grazing.
"We’re looking forward to continuing our work this year, no two years are ever the same, that’s why monitoring is so important. It will allow both ourselves and our clients to build up a picture over time of what’s happening not only on their individual farms, but potentially down to field level! This will allow us to provide more conclusive recommendations. For now, it’s clear that testing has great promise as a means to provide tailored advice to farms on how to control fluke and use the flukicides available to us responsibly.”
Emily says it’s important that farmers do not stop using flukicides based on the results of this study nor assume that there is less risk: “We all know how significant the losses from acute and chronic fascioliasis can be. We therefore encourage farmers to talk to their vet before they change their flukicide treatment protocols and discuss the possibility of using serology as an adjunct to determine how and when they treat.”
Veterinary professionals can find out more about the fluke sentinel project at https://xlvets-farm.co.uk/fluke-sentinel or the XLVets community at https://www.xlvets.co.uk/the-boss/.
Dechra Veterinary Products, manufacturer and distributor of Equipalazone®, has launched a new information leaflet to support the Equine Passport scheme.
Since 2005, when equine passports became mandatory, 958,000 have been issued. The passport is a method of identification as well as a medical record and ensures that horses treated with veterinary medicines do not enter the human food chain.
“Many substances used in commonly prescribed equine medicines can only be given to horses not intended for human consumption,” says Giles Coley, Dechra’s managing director. “Under the passport scheme, owners must declare whether their horse is intended for human consumption.
The leaflet, which outlines the importance and benefits of the Equine Passport scheme, will be inserted into every box of Equipalazone Powder 100 sachets. It will also be made available for veterinary practices to hand out to their clients.
Practices wishing or order copies of the Equine Passport leaflet should contact Rachel Horton at Dechra on 01743 441 632.
New Horse Passport Guidelines come into force from 1 July 2009 which will require horses to be microchipped. However a recent poll on Horse & Hound Online has revealed that 75 per cent of those questioned were unaware of the new microchip legislation.
With this in mind, Bayer has produced a comprehensive marketing support package for equine vets which provides an overview of the new Horse Passport Guidelines 2009 together with a clear and concise summary of its requirements for vets and horse owners.
The Tracer Advance equine package contains a handy laminated bullet point guide to the new regulations, practice posters, client leaflets, client leave pieces, pre-written articles for use in practice newsletters and local press, and PowerPoint presentations for client evenings.
Practices can apply for any of these items by contacting their Bayer Territory Manager.
Hill's Pet Nutrition has announced an average price reduction of over 5 per cent across almost 80 per cent of its product range from 1st March 2010.
The company says this is the first time in its history that such a big price reduction has been implemented, and it comes with a promise that superior nutritional quality won't be compromised.
The price cut comes following market research by Hill's which shows that after one of the deepest recessions in 50 years, more pet owners are becoming cost-conscious, and many are now buying their petfood in the grocery channel or mixing premium foods with economy products.
Another factor in decision-making for some pet owners is the cost per pack, particularly on the larger bag sizes. From April 2010, some Hill's Prescription Diet products will be resized to make them a more affordable purchase. Canine Prescription Diets c/d, d/d, i/d, k/d and j/d will be moved from a 14 Kg bag to a 12 Kg bag. Feline Prescription Diets c/d, k/d, r/d, i/d and s/d will be moved from a 2 Kg bag to a 1.5 kg bag. The price reduction will also be applied proportionately alongside the smaller bag size, so many clients should see a significant reduction at point of purchase. The smaller bags are also easier for practices to store and can increase frequency of client visits providing more opportunities to offer advice and support.
Blake Hawley, Hill's General Manager for UK and Ireland said, "We would like to thank vets, nurses and support staff for their continued support and dedication. Every pet needs and deserves a nutritional assessment and this price reduction will make it easier for vet teams to recommend the best Hill's product, confident those pets are getting high quality nutrition at new, lower prices. Having listened to what the profession had to say in 2009, this year we will demonstrate our commitment to the veterinary profession in very clear and visible ways."
For an up to date price list and support material to assist in communicating the change to clients, please contact your Hill's Territory Manager or call 0800 282438
Improve International has announced the launch of a new General Practitioner Certificate in Dermatology: GPCert (Derm).
The company says the programme aims to help vets develop their knowledge of dermatology and to assist them in applying these newly learned skills in their everyday dermatology cases.
David Babington MRCVS (pictured right), Managing Director of Improve International said: "Patients with skin problems attend practices almost on a daily basis, making the successful diagnosis and management of skin disease a major component of small animal work and an important way to build client satisfaction and loyalty.
"Our new modular programme offers a thorough, informed case-based approach to dermatology. Through lectures, case discussions and, where appropriate, practical sessions, delegates will learn how to approach dogs, cats and exotic patients presenting with various manifestations of skin disease in a logical and scientific manner."
The GPCert (Derm) comprises 14 taught modules and can be completed over one to two years. The first module on this programme will start in March 2015.
For further information, visit www.improveinternational.com or call 01793 759159.
The new award, sponsored by Krka UK, will recognise an exceptional farm vet who has been working in the dairy industry for three to five years and who has contributed significantly to the health and wellbeing of herds under their care.
Sarah Tomlinson, veterinary surgeon at Westpoint Farm Vets in Derbyshire, Technical Director of the TB Advisory Service (TBAS) and recipient of the 2020 Dairy Vet of the Year, said: “In recognising achievement among more recently qualified vets with this new award, Krka is giving the boost every young vet needs to shake off the ‘new grad’ title and instead become an ‘high performing’ vet, judged by their industry peers to be one of the best. Many vets can suffer with imposter syndrome so it is important that we accept positive acknowledgement of our work and our everyday achievements so that we can be rightly proud of what we do.”
More information about the CREAM Awards and the nomination process can be found here: https://www.britishdairying.co.uk/cream-awards-2021/
FMDMost of you will be aware that IP8 was declared yesterday. This is a farm in the POZ that was slaughtered on suspicion after detection during surveillance visits. This has lead to further slight changes in the boundaries of the PZ and SZ. These were early lesions and initial laboratory results confirm this.
The epidemiology of the spread of FMD in the area north of Egham suggests that cattle on 4 premises in the vicinity of IP8 have been exposed to infection either via possible aerosol or fomite spread and are likely to develop disease. These premises will be culled as dangerous contacts.
BLUETONGUEThe various zones for controlling Bluetongue have now been defined. These are difficult to describe because they use roads etc. as boundaries but detailed maps and description of the boundaries are available at:
http://www.defra.gov.uk/animalh/diseases/notifiable/bluetongue/pdf/declaration-bt-pzcz290907.pdf
When farms straddle a road that is a boundary the whole of the farm is classed as being in the zone. It may be possible to put parts of a holding that is outside the zone as a separate unit with consultation with local Animal Health office.
The movement restrictions between the various FMD and BT zones are available at
http://www.defra.gov.uk/animalh/diseases/notifiable/bluetongue/movements/index.htm
Defra are worried that farmers are not reporting cases of BT because they feel there is nothing that can be done so why bother. It is still a notifiable disease and there is a need to monitor spread for various trade implications. There are, of course, likely to be welfare considerations with clinically affected cases. These will need to be addressed with veterinary consultation and may involve symptomatic treatment or euthanasia.
The prevalence of the disease in infected herds/flocks is still low with 1:53 and 1:190 being affected on surveillance.
A series of exchanges between pilots and control towers, which you might find amusing. Would be nice to have some veterinary equivalents, so do feel free to comment beneath this story with any quick-witted exchanges you've heard between vets and vets / nurses / clients.
San Jose Tower to a DC-10 that had come into land too fast, and thus had an exceedingly long roll out after touching down:"American 751, make a hard right turn at the end of the runway, if you are able. If you are not able, take the Guadeloupe exit off Highway 101, make a right at the lights and return to the airport." ***************************************************************
Tower: "TWA 2341, for noise abatement turn right 45 degrees." TWA 2341: "Center, we are at 35,000 feet. How much noise can we make up here?" Tower: "Sir, have you ever heard the noise a 747 makes when it hits a 727?" ***************************************************************
Tower: "Eastern 702, cleared for takeoff, contact Departure on frequency 124.7" Eastern 702: "Tower, Eastern 702 switching to Departure. By the way,after we lifted off we saw some kind of dead animal on the far end of the runway." Tower: " Continental 635, cleared for takeoff behind Eastern 702, contact Departure on frequency 124.7. Did you copy that report from Eastern 702?" BR Continental 635: "Continental 635, cleared for takeoff, roger; and yes, we copied Eastern... we've already notified our caterers." ****************************************************************
A BA 747, callsign Speedbird 206 landed at Frankfurt aiport and was just pulling clear of the runway
Speedbird 206: "Frankfurt, Speedbird 206 clear of active runway." Frankfurt ground: "Speedbird 206. Taxi to gate Alpha One-Seven." The BA 747 pulled onto the main taxiway and slowed to a stop. Frankfurt ground: "Speedbird 206, do you not know where you are going?" Speedbird 206: "Stand by, ground, I'm looking up our gate location now." Frankfurt ground (with quite arrogant impatience): "Speedbird 206, have you not been to Frankfurt before?" Speedbird 206: "Er yes, just the once. It was 1944 ... We didn't land."
Dechra Veterinary Products has picked up a major award at the 2011 Veterinary Marketing Awards for a calendar called 'The Horse in History'.
The calendar, designed to promote all of Dechra's equine products but particularly Equipalazone, also won the award for most innovative use of direct mail. The company's website, http://www.dechra.co.uk/, was highly commended in the New Media category.
The John O'Hara Award is made to the VMA category finalist which, in the opinion of the judges, best demonstrates a high level of innovation or adventurousness in an aspect of the advertising mix. Designed to celebrate the unique position of the horse down the ages in culture, art, science and legend, the calendar featured twelve iconic illustrations, from the white horse carved into the chalk hillside in Uffington, Oxfordshire, to Da Vinci's sculpture.
It also included an embedded competition giving practices the opportunity to win practical aids, including wind up torches and water bottles, with the major prize being a trip to Vienna to see the Lipizzaner Stallions at the Spanish Riding School.
Larry King, Senior Brand Manager at Dechra, said: "Horses have had a unique relationship with man for thousands of years and this is what we wanted to celebrate with our calendar. The monthly competition with 100 prizes on offer and the special prize draw at the end of the year gave it a real point of difference and it proved very popular with our customers. It was the first time we'd run such a campaign over twelve months and we believe it to be unique in the animal health sector.
"We were delighted and honoured to win both the award for best use of direct mail and the John O'Hara award for The Horse in History. It will inspire us on our quest to continually set new standards in the way we communicate with our customers."
The Norman Cavalry
Galloping Horse
The Uffington White Horse
The Anatomy of The Horse
Incitatus
Bucephalus
Altamira Cave Painting
Gran Cavallo
Rocinante
American Carousel Horse
Aethenoth
The Pet Food Manufacturers Association (PFMA) has published the results of research which found that veterinary surgeons believe 45% of all pets are overweight.
In addition, 77% of the 180 vets surveyed at the London Vet Show 2013 believe that the pet obesity problem is on the rise.
Meanwhile, 93% of pet owners said they would be concerned to discover their pet is overweight, revealing a sharp divide between vets' and owners' perceptions.
To help spread the word about ideal pet weight, the PFMA will launch a new campaign called #GetPetsFit on 7th May.
Michael Bellingham, Chief Executive of PFMA said: "We need to engage pet owners emotionally, helping them realise that feeding and exercising their pet to the optimum level can result in an extra two years of active life. The #GetPetsFit campaign will provide the perfect opportunity to do this and we hope that with the help of vets, we can work to resolve this important issue."
The PFMA is urging practices to promote good nutrition and a healthy lifestyle. Zara Boland BVSc BE MRCVS, Founder of Vet Voice Ltd says: "It is encouraging that success rates are high for the 78% of UK vets already running companion animal obesity clinics. However, we must continue pushing the health message until overweight pets are no longer seen as the 'norm'. We need widespread recognition of pet obesity to pave the way for positive action."
One way that the PFMA is encouraging practices to get involved is by running Weigh in Wednesdays from 7th May. To help, the organisation has prepared a free kit that contains campaign posters, website banners and client hand-out materials, including Pet Size-O-Meters (for cats, dogs, rabbits and birds), a pet food diary and weight and body condition log. You can either download the kit here: www.pfma.org.uk/weighinwednesday or visit PFMA's homepage and ask for a free pack to be sent to your practice.
The panel, chaired by veterinary ethicist Professor David Morton CBE, was established last year on a trial basis as a means of offering an ethical review process for practice-based research projects that may not have the same access to resources as clinical studies in academia or industry.
Since its establishment at the end of July last year it has received 23 applications, mostly concerning small animal clinical studies. However, due to demand from the profession, it will shortly be considering applications for equine or farm animal-based research and will be recruiting new panel members to cover these areas.
Eleanor Ferguson, RCVS Registrar, said: "Although the number of cases considered so far have been relatively small, the service has been very well received as a means of providing ethical review to those who might not otherwise be able to do so and so, therefore, might struggle to get papers published.
"Considering the importance of practice-based research we expect there to be an increase in the number of applications as word gets out about the service and so are happy to extend the trial for another year and for it to consider a wider range of applications."
Further details about the Panel, as well as guidelines for making applications and the application forms, can be found at www.rcvs.org.uk/ethics
For an initial discussion about submitting an application to the Ethics Review Panel, contact Beth Jinks, Standards and Advisory Officer, on 020 7202 0764 or ethics@rcvs.org.uk
There have been major changes to the format for Congress this year.
Sarah Fitzpatrick, BSAVA Head of Partnerships and Events, said: “Last year’s online event proved this can all be delivered in a much more interactive and engaging way.
"Returning to a face-to-face format enables us to take that even further and provide delegates with a truly immersive experience."
Many of the sessions at this year’s event will have two speakers delivering different perspectives on a topic, followed by a Q&A.
With 15-20 minutes to get into the detail, lectures will get straight to the point, be fast-paced and rich in content.
Programme committee lead, Paul Higgs (pictured right) said: “Each subject will be delivered in a mix of formats, lectures, debates and interactive sessions, for example.
"It means delegates won’t find themselves sat for hours passively listening, instead they’ve the opportunity to actively engage with the topics, which will promote deeper learning.
“Where topics overlap subject areas, module delegates will come together to explore diagnostics, treatments and ethics.”
For the first time, delegates will also be able to get hands-on in practical sessions at no further cost.
BSAVA’s President, Sheldon Middleton, said: “I can’t wait to get to BSAVA Congress in 2022.
"The new venue, new format and new exhibition layout will enhance everything that BSAVA Congress is known for.
"Now we’ve got a hybrid format, the on-demand feature means that for the first time I can catch up with friends and not miss the CPD!”
Delegates can also attend online, through an interactive virtual platform, which will run alongside the live event.
To buy your tickets before the touts get hold of them visit: https://www.bsavaevents.com/bsavacongress2022/en/page/home.
Dechra Veterinary Products has launched a calculator which provides vets with an instant analysis of how much they can save when stocking veterinary licensed generic products over an equivalent.
The new margin calculator enables practices to manipulate their mark-ups for a greater increase in profit while also providing cost savings for clients.
Roger Brown, product manager at Dechra Veterinary Products said: "With the rise of veterinary licensed generic products on the market, our calculator provides practices with an added opportunity to increase their own profitability. This can be achieved through a simple re-calculation based on the purchase price of a product, versus its mark-up and how much they are sold on to clients for. In many circumstances, practices will see an increased profit for themselves and cost reductions for the client – everyone wins!"
The margin and profit calculator compares market prices with Dechra’s own generic range – Veterinary Essentials – to show just how much mark-up can be applied to products without impacting on a client’s budget.
Roger added: "It’s a simple, but very effective calculation. The beauty is that this calculator can be run from any computer and does not require supporting software."
For more information about the margin calculator please contact your local Dechra territory manager or call Rachel Horton on 01743 441 632.
Vetoquinol has launched a pain monitoring system along similar lines to those used in humans, which can be used by vets and owners to measure pain over time and assess different treatment strategies in dogs.
According to the company, it is widely accepted that all mammals experience pain1and that under treatment is a big issue. Guidelines in treating human pain issued by NICE state that: 'evidence suggests that pain caused by advanced disease remains under-treated'. Veterinary medicine faces a harder task in recognising and treating pain effectively as it relies on behaviour rather than verbal communication.
In human medicine, Client Specific Outcome Measures have been used to assess treatment strategies focussing on identifying the degree of difficulty performing daily tasks on an individual patient to patient basis. Vetoquinol says its pain monitoring system is based on similar principles.
Robert Simpson, Product Manager for Cimalgex said: "The objective assessment of clinical outcomes are a continuing challenge in veterinary medicine; this is particularly true in chronic painful conditions such as osteoarthritis. Use of our Client Specific Outcome Measures form will allow vets and pet owners to more efficiently assess treatment to ensure that the patient is receiving appropriate analgesia.
The form can be adapted to give bespoke outcome measures which are agreed in consultation with the owners. This activity will increase interaction with pet owners and could increase loyalty to the practice; it could also be really useful in geriatric clinics etc as a method of assessing pain outside of consultations in practices."
To find out more or to request a monitoring pad for your practice, contact your Vetoquinol Territory Manager or call 01280 825424.
A team of top equine vets is aiming to raise £125,000 for the Society for the Protection of Animals Abroad (SPANA) by travelling 3000 miles through Europe by motorbike between 22nd August and 9th September.
Sponsored by Elanco Animal Health, the seven-strong team is planning to travel through Belgium, the Netherlands, Germany, Switzerland, France, Italy, Morocco and Spain and deliver lectures to eight European and African veterinary schools in just two weeks.
Led by Professor Derek Knottenbelt from the University of Liverpool, the team also includes Professor Josh Slater from Royal Veterinary College, Dr John Burford from the University of Nottingham, Dr Caroline Hahn from the University of Edinburgh, Dr Michael Hewetson from the University of Helsinki, Ms Joanne Suthers from the University of Liverpool and Dr Edmund Hainisch from the University of Vienna. They are being supported by Jeremy Hulme, chief executive of SPANA, Nic Van Gelder, fundraising and supporter care administrator at SPANA and Cerian Stephens.
All money raised will provide SPANA with diagnostic and surgical equipment for the charity's veterinary clinics for working animals in Mali and Mauritania and for the further development of the Bamako Disabled Riding Centre in Mali.
Mike Brown, Elanco's UK and Ireland country director said: "We are delighted to be sponsoring the Vets with Horsepower European Tour which will raise vital funds for working animals in some of the world's poorest countries. This is just one of the many worthwhile initiatives we are supporting in 2012 which focus on alleviating world hunger, spearheading agricultural leadership, enhancing the human-animal bond and caring for the environment."
For further information on the Vets with Horsepower European Tour visit www.spana.org/horsepower.
Elanco has announced the results of a survey it conducted amongst European dermatology diplomates which found that nearly 90% of them consider Comfortis (spinosad) is the first choice of flea control for cats and dogs.
The research was conducted at the European Society of Veterinary Dermatology (ESVD) and European College of Veterinary Dermatology (ECVD) Congress 2013. 49 Dip ESVD holders from around Europe were asked:
Research has shown that dermatological cases account for approximately 20% of small animal consultations conducted by general practitioners1. According to Elanco, further industry investigations have found that skin diseases are two to three times more common than the next disease category, and dermatological problems are a common secondary reason for an examination.
Anna Jackson, national veterinary manager at Elanco Companion Animal Health, said: “Skin diseases are a huge part of a practicing vet’s workload and one which can prove challenging to effectively address. By creating a fast acting oral flea control product that can work alongside other topical dermatological treatments, we’re helping to alleviate the discomfort and consequences of flea allergy dermatitis, which is one of the most common causes of skin disease. It’s fantastic to receive such strong endorsements from some of the leading dermatologists in Europe and this underlines the benefits of using Comfortis for flea control.”
Reference
Zoetis has announced that it has upscaled production of Apoquel, the oral therapy for the treatment of canine pruritus, and it is now available to all UK vet practices on unlimited distribution.
The company says that there was unprecedented demand for Apoquel following its launch last year, so it had to introduce an allocation system to ensure that those dogs that had started on the product were able to remain on it for as long as their vet deemed appropriate.
During this time, Zoetis focused on strengthening its manufacturing capacity to make the product more widely available.
Apoquel is the first Janus Kinase (JAK) inhibitor approved for veterinary use. Zoetis says it provides rapid and sustained relief of pruritus and improves skin lesions. Its novel mechanism of action on the JAK enzyme is specifically designed to target the pruritogenic and pro-inflammatory pathways involved in the itch cycle. This, says the company, allows effective reduction of allergic itch regardless of its cause as well as improvement of skin lesions associated with allergic skin diseases and atopic dermatitis.
Ned Flaxman, companion animal business unit director at Zoetis said: “We are very grateful to all our veterinary customers for bearing with us through this product shortage. Over the past 18 months we have incorporated a variety of safeguards to ensure that Apoquel supply will better align with demand. We have reduced the length of time it takes to manufacture Apoquel and added further production capacity.
“It’s been a very long 18 months for everyone involved but we’re looking forward to a very good Christmas and New Year with Apoquel fully back in stock and we’d like to thank all of our customers for their patience.”
For more information, visit www.zoetis.co.uk/apoquel.